Background and aims: Methotrexate (MTX) is sometimes used as part of combination therapy for the treatment of inflammatory bowel disease [IBD]; however, the optimal MTX dose for combination therapy has not been established. This study compared the efficacy of lower-dose and higher-dose MTX with anti tumor necrosis factor alpha (anti-TNF) therapy among IBD patients. Conclusions: When combined with anti-TNF therapy, MTX at doses of >12.5 mg/week was more effective at maintaining clinical remission than lower doses. These findings will guide management of combination therapy in IBD patients.
Introduction
Sixty years after it initially gained Food and Drug Administration (FDA) approval for the treatment of leukemia, methotrexate (MTX) is now one of the primary immunomodulator therapeutic agents used as 'off-label' therapy for the induction and maintenance of IBD treatment. 1 Although it has become more commonly used in current clinical practice, its utility in IBD was not made apparent until it was used to treat leukemia in patients with comorbid autoimmune disease. These patients demonstrated parallel improvements in both hematological malignancy and autoimmune activity, thus providing initial evidence for the immunomodulatory capabilities of MTX. 2 In rheumatoid arthritis, MTX has become one of the main treatments for achieving remission, both as monotherapy and, importantly, as combination therapy with anti tumor necrosis factor alpha (anti-TNF) agents. 34, 5, 6 For the past two decades MTX has been increasingly used for the treatment of IBD, particularly among patients with Crohn's disease (CD 7, 8, 9, 10, 11 In addition to MTX's primary efficacy in CD and possibly UC, there has been increasing interest in its utility as a combination therapy with anti-TNF biologic treatments. A recent study within the IBD patient population has demonstrated that concurrent MTX use prevents formation of antibodies in CD patients. 12 Whereas the complementary nature of the methotrexate and biologic medication is clear, the precise efficacy and optimal dosing of dual therapy in IBD has yet to be established. 456 In addition, it is unknown whether oral or parenteral administration of MTX as combination therapy is more effective. In contrast, among patients with rheumatoid arthritis, lower doses of oral MTX are recommended at induction and are escalated when required based on response and tolerability. 13 The aims of this study were to assess and compare the duration of remission and tolerability between different dosing regimens of MTX in IBD patients who were concomitantly prescribed anti-TNF therapy. The primary outcome of duration of remission maintenance was defined as consecutive months in clinical remission until clinical relapse. Secondary outcomes included indicators of worsening disease within a 6-month period [indicated by endoscopic inflammation, corticosteroid use, therapy escalation, addition or escalation of concomitant therapy, or surgery] and occurrence of adverse events.
Materials and Methods

Patient selection and ethical statement
Statistical considerations
The primary outcome of consecutive months in clinical remission until relapse was assessed by Kaplan-Meier survival analysis. A log-rank test was used to assess the difference between the two groups. Objective measures of disease-worsening were registered and dummy-coded [with a 1 for worsening and 0 for stable disease].
The total number of disease-worsening events were calculated per regimen category and compared by chi-square analysis. Logistic regression was used to assess for factors that could predict LD versus HD regimens. Adverse events were assessed based on whether dose change such as de-escalation 
Adverse events
Of the 73 patients in our cohort who were prescribed MTX combination therapy, 18% [13] reported an adverse event during follow-up. Of the total cohort of patients who achieved remission, this particular patient cohort comprised 13%. Adverse events were more frequently reported in HD-MTX patients (33% [n = 7]) than LD-MTX patients (12% [n = 6]), but this difference was not statistically significant [p = 0.13]. In these 13 patients there were 17 adverse events. Nausea and/or vomiting was the most common [n = 6] followed by abnormal liver chemistry (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] defined as more than twice the upper limit of normal) [n = 4]. Other adverse events included fatigue, low-grade fever, headache, general malaise, rash, and joint pain as illustrated by [ Table 2 ].
Eight patients elected to change therapy due to adverse events. Two of these patients de-escalated MTX dose and the remaining 6 discontinued MTX therapy completely. Discontinuation occurred in 6% [n = 3] of LD-MTX patients and 14% [n = 3] HD-MTX patients [p = 0.34]. Discontinuation due to adverse events was similar for both the responder [7%, n = 3/46] and non-responder groups, with 7% and 11% of patients terminating therapy, respectively [p = 0.66]. Table 3 illustrates the details of adverse events between HD-MTX and LD-MTX patients. Patients who achieved remission on methotrexate and concomitant anti-TNF agents were observed for a total of 198 6-month review periods. During this interval, an increase in incidents of worsening disease [as indicated by endoscopic inflammation, corticosteroid use, therapy escalation, addition or escalation of concomitant therapy, or surgery] occurred in 34.4% of LD-MTX periods and 31.4% of 
Patients in remission
Discussion
To our knowledge, this is the largest study of clinical outcomes using concomitant MTX with anti-TNF therapy in a real-world IBD practice to date. We found that MTX doses of 15-25 mg/week in combination with anti-TNF biologic therapy are more likely to maintain clinical remission than MTX of ≤ 12.5 mg/week in combination therapy. However, dose of MTX was not associated with secondary measures of disease control, including anti-TNF dose change, corticosteroid use, endoscopic inflammation, or surgery. Randomized controlled trials of LD-MTX monotherapy in both CD and UC previously have failed to demonstrate any greater benefit in prevention of flares compared with HD-MTX. 14, 15 A recently published combination therapy study of infliximab and HD-MTX administered subcutaneously [up to 25mg /week] versus infliximab plus placebo did not report improved treatment efficacy. However, this study was limited in that both groups received corticosteroids during infliximab infusions. 12 However, patients in the combination therapy group had a lower rate of immunogenicity and higher trough levels. Notably, endoscopic activity was not assessed in this study. Additional studies that assessed combination therapy in IBD and included MTX as one of the agents are sparse, and are limited to assessment with infliximab only. At this time, there have only been two studies that compared azacitidine [AZA] to MTX [on 15-mg/ maintenance dose] while these medications were used as part of combination therapy. Sokol and colleagues found that combination therapy of AZA, but not MTX, was associated with decreased occurrence of abdominal surgery or switch to adalimumab. 16 Vermeire et al. found that MTX and AZA prevented antibodies in combination therapy equally well. Clinical outcome was not assessed. 17 In our cohort, the rate of side effects was higher among patients receiving HD-MTX. The side effect profile of MTX is well known to be dose-related, so this result is not surprising, but may have influenced the clinical interpretation of efficacy as well. Despite this, there was no difference between the two groups in the need for a regimen change due to adverse events. Of note, adverse events were only documented when they occurred while a patient was concurrently prescribed folic acid and ondansetron in addition to MTX. Previous clinical trials have demonstrated high withdrawal rates [up to 17%] due to adverse events among MTX-prescribed IBD patients. 7 Among patients receiving 15-25 mg, the withdrawal rate due to adverse events [14%] in our MTX cohort was comparable with this finding. The adverse event rate within this cohort was 18% overall, and up to 33% in the HD regimen group. A meta-analysis by Valentino et al. found that all [paediatric] studies that reported hepatotoxicity during MTX administration had a pooled rate of 10.2% for hepatotoxicity prevalence, requiring dose-reduction in 6.4% and discontinuation in 4.5%. 18 In our cohort, 5% [n = 4] of patients were found to have increased transaminases of more than twice the upper limit. Of these patients, two [1 LD and 1 HD] had to discontinue MTX and one [1 HD] underwent change of dosing.
This study has several methodological limitations. It was a retrospective analysis that was completed in a tertiary center among patients who have relatively complex IBD. Therefore, patients who failed previous anti-TNF therapy and had prior surgeries were included and comprised a greater percentage of patients than might exist within a community sample. In addition, as many of the measures included in this study are subjective, outcomes may have been influenced by the report bias of the physician or patients. It is also possible that the dosing regimens utilized by the patients included within the study may not be indicative of dosing trends within the population at large. Whereas we believe that the dosing trends within this institution reflect standard-of-care clinical practice, it is possible that they may reflect a biased patient sample population that reflects the disease severity of the patient cohort. We argue that the trend for lower MTX dose does not reflect a less severe patient cohort and instead is indicative of merging clinical practice in the field. To the same extent, one might argue that a subset of these patients may have had less severe disease if the prescribing physician initially started the patient on MTX monotherapy and added concomitant anti-TNF therapy at a later point in treatment. This does not appear to be the case-when examining at our primary outcome group [patients who continued therapy during the maintenance phase], only 2 patients received anti-TNF therapy after induction with MTX therapy. These included 1 patient on LD-MTX and 1 on HD-MTX. As such, we may conclude that disease-severity at inclusion did not plausibly influence our primary outcome measures.
Another limitation to this analysis is the lack of available therapeutic drug levels in all patients, which could have provided additional objective information about disease control. However, additional information about therapeutic drug levels would not have affected our primary outcome, as clinical remission is defined by the clinical disease indices HBI or SCCAI and not by the presence of therapeutic drug levels.
Of note is the mix of parenteral and oral dosing regimens with MTX. The total number of parenteral patients was too small to characterize the MTX route of effective administration, but prior research suggests relative bioequivalence and clinical outcomes of oral and subcutaneous MTX in patients with CD. [19] [20] [21] However, there are conflicting data about the bioavailability of HD-MTX [25 mg or more]. 22 Bioavailability is an important index of quality control, but serum levels themselves may lack the sensitivity and/ or specificity to adequately compare outcomes. More studies that explore therapeutic drug monitoring and the relationship between drug levels and clinical outcomes are needed. These may require the inclusion of MTX substrates such as intracellular polyglutamates. 23 Future research should include a prospective trial that compares combination therapy of an anti-TNF agent with MTX [in low, high, ora,l and injectable regimens] versus anti-TNF combination therapy with a different immunomodulator class. Additionally, it would also be of great interest to compare the effectiveness of immunogenicity prevention among different immunosuppressive agents.
In conclusion, we found that combination therapy of anti-TNF biologics with MTX at doses of 15-25 mg/week [either orally or subcutaneously administered] are superior in maintaining clinical remission compared with MTX at lower doses, but found no differences in secondary measures of disease activity. Our finding of more adverse events in HD-MTX supports the need to balance efficacy with tolerability, to optimize management of IBD patients receiving anti-TNF therapy.
As the management of IBD continues to support combination therapy approaches, the findings of this study have important implications for the successful use of MTX as concomitant therapy for our IBD patients.
